PharmX Technologies Limited

As of June 30, 2025, PharmX Technologies Limited carries a market capitalization of 55.66M, placing it among publicly traded companies globally. Its enterprise value stands at 52.38M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PharmX Technologies Limited's next confirmed earnings release is scheduled for February 25, 2027.

As of June 30, 2025, PharmX Technologies Limited has 598.51M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 7.60, and the price-to-book ratio stands at 3.49.

These figures are as of June 30, 2025. The EV/Sales ratio of 7.16 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 52.38M versus a market cap of 55.66M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, PharmX Technologies Limited maintains a current ratio of 3.33, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.61, indicating elevated leverage, while an interest coverage ratio of -4.68 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2025, PharmX Technologies Limited posted a negative return on equity (ROE) of -1.66, meaning shareholder capital produced losses rather than profits. Return on invested capital (ROIC) comes in at 28.79 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) is negative at -1.08, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -2.23, pointing to unprofitable operations over the period.

Over the twelve months ended June 30, 2025, PharmX Technologies Limited recorded 343,000.00 in income tax expense. That works out to an effective tax rate of 434.18, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 79,000.00, leaving -264,000.00 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, PharmX Technologies Limited's stock has declined approximately 42.40% over the past 52 weeks. The 50-day moving average sits at 0.09, while the 200-day moving average is 0.11.

Over the twelve months ended June 30, 2025, PharmX Technologies Limited generated 7.32M in revenue and converted that into -264,000.00 in net income, yielding earnings per share of 0.00. EBITDA reached -145,000.00, while operating income came in at -1.42M.

As of June 30, 2025, PharmX Technologies Limited holds 4.17M in cash and equivalents against 894,000.00 in total debt, resulting in a net debt position of -4.17M. Total book value stands at 15.93M, with working capital of 4.03M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

Over the twelve months ended June 30, 2025, PharmX Technologies Limited posted a gross margin of 81.43, reflecting its pricing power and cost economics. The operating margin of -19.44 and net profit margin of -3.61 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield reaches 0.24, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PharmX Technologies Limited shareholders.

PharmX Technologies Limited's most recent stock split took place on September 4, 2020 with a 201:212 split ratio.

As of June 30, 2025, PharmX Technologies Limited has an Altman Z-Score of -2.99, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.